Esperion Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ESPR research report →
Companywww.esperion.com
Esperion Therapeutics, Inc. , a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.
- CEO
- Sheldon L. Koenig
- IPO
- 2013
- Employees
- 304
- HQ
- Ann Arbor, MI, US
Price Chart
Valuation
- Market Cap
- $650.75M
- P/E
- -105.99
- P/S
- 1.56
- P/B
- -2.55
- EV/EBITDA
- 9.68
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 65.00%
- Op Margin
- 18.12%
- Net Margin
- -1.77%
- ROE
- 1.99%
- ROIC
- 46.25%
Growth & Income
- Revenue
- $403.13M · 21.31%
- Net Income
- $-22,682,000 · 56.17%
- EPS
- $-0.11 · 60.71%
- Op Income
- $60.27M
- FCF YoY
- 45.38%
Performance & Tape
- 52W High
- $4.18
- 52W Low
- $0.76
- 50D MA
- $2.55
- 200D MA
- $2.90
- Beta
- 0.91
- Avg Volume
- 12.08M
Get TickerSpark's AI analysis on ESPR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 17, 26 | Looker Benjamin | sell | 5,708 |
| Mar 17, 26 | Koenig Sheldon L. | sell | 25,578 |
| Mar 17, 26 | Halladay Benjamin | sell | 6,424 |
| Mar 13, 26 | Looker Benjamin | other | 300,840 |
| Mar 13, 26 | Looker Benjamin | other | 269,230 |
| Mar 13, 26 | Koenig Sheldon L. | other | 723,760 |
| Mar 13, 26 | Koenig Sheldon L. | other | 647,460 |
| Mar 13, 26 | Halladay Benjamin | other | 247,430 |
| Mar 13, 26 | Halladay Benjamin | other | 221,270 |
| Jan 20, 26 | Looker Benjamin | sell | 1,689 |
Our ESPR Coverage
We haven't published any research on ESPR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ESPR Report →